TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary) ; Zoledronic acid (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacodynamics
- Acronyms TAME
- 12 Sep 2023 Planned End Date changed from 31 Mar 2023 to 2 Feb 2027.
- 12 Sep 2023 Planned primary completion date changed from 31 Mar 2023 to 2 Feb 2027.
- 12 Sep 2023 Status changed from recruiting to active, no longer recruiting.